The Supreme Court's May 2026 shadow docket denied redistricting stays and halted a Fifth Circuit mifepristone dispensing order, with Thomas and Alito dissenting.
The Supreme Court issued a cluster of emergency docket orders in mid-May 2026, denying or dismissing stay applications in two redistricting disputes while separately pausing a lower court order that would have restricted mifepristone dispensing. The orders, issued without full briefing or oral argument, illustrate how the Court's interim docket continues to serve as a first-mover on questions with immediate electoral and public-health consequences [1].
On the redistricting front, the Court denied an application on May 22 to vacate an outstanding stay, following a May 15 denial of a separate stay application in a Virginia redistricting matter [1]. Justice Clarence Thomas, acting in his capacity as Circuit Justice, denied on May 11 as moot two emergency stay applications in Alabama redistricting cases, Allen v. Caster and Allen v. Milligan [1]. The mootness disposition in the Alabama matters closed off immediate Supreme Court intervention without resolving the underlying map disputes on the merits [2].
The mifepristone orders moved in the opposite direction. On May 14, the full Court granted stays in Danco Laboratories v. Louisiana and GenBioPro v. Louisiana, halting a Fifth Circuit order that would have imposed in-person dispensing requirements on the drug [1]. Justices Thomas and Samuel Alito dissented from the grant of those stays, putting on record their view that the lower court's dispensing restrictions should have been allowed to take effect [1]. The stays preserve pharmacy-dispensing access to mifepristone while the underlying litigation proceeds through the Fifth Circuit and, potentially, back to the Court on the merits [2].
Taken together, the orders reflect a Court managing simultaneous emergency queues across two of the most contested domains in American public law: voting-district lines that will govern the 2026 midterm cycle and medication-abortion access that remains contested in multiple circuits following the Court's 2022 Dobbs decision [2]. The shadow docket's speed, limited reasoning, and split-dissent pattern on the mifepristone stays draw attention to how consequential relief is granted or denied without the deliberative record that accompanies a fully argued case [1].
Practitioners and court-watchers should monitor the Fifth Circuit's merits schedule in the Danco and GenBioPro matters, as well as any renewed filings in the Virginia redistricting litigation, where the underlying map challenge has not been resolved [1] [2].